Demographics and clinical characteristics were similar between treatment groups except for a slight trend toward decreased tibialis anterior muscle strength in the treatment group ( Table 1 ).
← all excerpts
Erythromycin for myotonic dystrophy type 1: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
1
—
—